ArticleThoracic cancer2025
Progression-Free Survival Prediction Model Based on AI-Enhanced Dynamic Radiomics for Personalized EGFR-TKI Treatment Monitoring Patients With Lung Adenocarcinoma.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pathomics-based machine learning models for predicting METTL5 expression and prognosis in lung adenocarcinoma.Journal of thoracic disease · 2026Article
- Predicting primary resistance to third-generation EGFR-TKIs in lung adenocarcinoma using a multisource cross-modal transformer model.NPJ precision oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND AND
objectiveEpidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line treatment for patients with advanced lung adenocarcinoma (LUAD) with EGFR mutations. However, treatment effectiveness varies widely among individuals, and effective models to predict treatment response are lacking. This study aims to establish a progression-free survival (PFS) prediction model based on dynamic changes in pre- and post-treatment CT scans combined with patients' clinical features.
methodsA total of 183 patients with advanced LUAD who received first-line treatment at Peking University Third Hospital from January 2013 to December 2022 were enrolled. A 3D-UNet model was fine-tuned using data from 405 patients with non-small cell lung cancer for advanced lesion segmentation. Clinical and radiomic features extracted using 3D models from 80 EGFR-mutant LUAD patients were used to develop PFS prediction models with a deep-learning binary classification model. The accuracy, specificity, sensitivity, AUC, and F1 score of the models were validated in patients with mutant and wild-type EGFR.
resultsIn the EGFR-mutant test set (N = 53), the AUC for the 9-month and 12-month progression prediction models were 0.858 (95% CI, 0.707-0.972) and 0.873 (95% CI, 0.747-0.974). Their accuracies were 81.1% (95% CI, 69.8%-90.6%) and 84.9% (95% CI, 73.6%-94.3%), specificities were 87.5% and 72.2%, sensitivities were 80.0% and 91.4%, and F1 scores were 0.878 and 0.889, respectively.
conclusionThis study developed treatment response prediction models for EGFR-mutant LUAD patients. These models demonstrated strong predictive value for PFS in patients treated with EGFR-TKIs, potentially enabling a more efficient personalized CT scan schedule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.